Resveratrol's Effects in Diabetic Nephropathy

• Status: Completed
• Trial end date: 2017-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the safety and effects of resveratrol in treatment of diabetic nephropathy.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shiraz University of Medical Sciences
• Treatments: Losartan; Resveratrol

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus (DM)

• Controlled blood sugar [fasting blood sugar (FBS) <130mg/dl and glycosylated hemoglobin (A1C)<7%

• Urine albumin >20mg/lit in two separate occasions during the last 3 months period

• Serum creatinin < or = 2mg/dl

Exclusion Criteria:

• Pregnancy

• Lactation

• Alcoholism

• Liver failure (acute or chronic)

• Renal failure: serum creatinin >2mg/dl

• Glomerulonephritis

• Uncontrolled hypertension

• Congestive heart failure

• Prostate disease

• Malignancy

• Bilateral renal artery stenosis

• Any systemic disease other than DM

• Any infection or rheumatologic disorder

• Use of warfarin